Stockscreener 앱 받기
0.3088
9.78%
0.0287
Soligenix Inc 주식(SNGX)의 최신 뉴스
TradingKey - TradingKey
Soligenix (SNGX) registers 1,054,688 resale shares; Q1 cash $6.03M - Stock Titan
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
HyBryte CTCL trial halted as Soligenix (SNGX) faces going concern risk - Stock Titan
Soligenix (SNGX) Faces Setback in FLASH2 Study Results - GuruFocus
Soligenix Releases Q1 2026 Financial Results - AlphaStreet
Soligenix 1Q Loss/Shr 28c >SNGX - Moomoo
Soligenix Announces Recent Updates And First Quarter 2026 Financial Results - TradingView
Soligenix Anticipates HyBryte™ Phase 3 Results in Second Half of 2026, Reports $28.3 Million in Cash - geneonline.com
Soligenix Q1 net loss narrows on lower expenses - TradingView
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - ChartMill
SNGX stock slumps to record low after lymphoma trial fails – all eyes now on Behçet’s disease treatment - MSN
A. G. P. Maintains Soligenix(SNGX.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
SNGX phase 3 trial halted on HyBryte - MSN
SNGX: FLASH2 Trial Recommended to Stop for Futility - Yahoo Finance
Soligenix signals pivotal year with new drug progress - Community News
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives - TipRanks
SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment - Stocktwits
SNGX Phase 3 Trial Halted on HyBryte - Yahoo Finance
Soligenix halts lymphoma drug trial after futility analysis - Investing.com UK
Disappointment in Interim Results for Soligenix (SNGX) in Phase 3 Trial - GuruFocus
Why Is Soligenix Stock Sinking Tuesday? - Benzinga
SNGX - Finviz
Soligenix halts lymphoma drug trial after futility analysis By Investing.com - Investing.com Australia
HyBryte FLASH2 failure leaves Soligenix (NASDAQ: SNGX) facing funding and pipeline risk - Stock Titan
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma – Company AnnouncementFT.com - Financial Times
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease (PR Newswire) - Aktiellt
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency (PR Newswire) - Aktiellt
Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach - TipRanks
Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - NewMediaWire
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status - TipRanks
Soligenix (SNGX) price target decreased by 14.29% to 15.30 - MSN
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results - The Globe and Mail
Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results - NewMediaWire
Soligenix secures EU orphan drug designation for Behçet’s disease therapy - MSN
Soligenix (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development - The Globe and Mail
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
3.14%
1.01%
자본화:
|
볼륨(24시간):